European Academy of Neurology (EAN) Congress 2025

Two separate randomized controlled trials (SUNRISE and RESOLUTION) have shown the superiority of eptinezumab over placebo in a predominantly Asian migraine population and in patients with chronic migraine (CM) and medication-overuse headache (MOH).

A study presented at EAN 2025 demonstrates a reduction in the risk of sudden unexpected death in epilepsy (SUDEP) following treatment with the antiseizure medication (ASM) cenobamate among Spanish individuals in the phase III C021 study. The reductions were based on SUDEP-3 and SUDEP-7 risk scores.